Takara Holdings Inc.
Notice regarding the disclosure of the Q1 2027 earnings report exceeding 45 days after the quarterly end
The disclosure of the Q1 2027 earnings summary is expected to exceed 45 days after the quarter end. The delay is due to uncertainties in the accounting treatment of Takara Bio USA, Inc. and delays in audit conclusions. The date for the decision is currently undetermined.
Key Figures
- Takara Bio USA, Inc. sales (past 3 years): 2023 Jan-Dec 12,0786 thousand USD, 2024 Jan-Dec 11,3029 thousand USD, 2025 Jan-Dec 10,7217 thousand USD
- Delay in disclosure of quarterly earnings summary: expected to exceed 45 days
- Current status of earnings announcement date: undetermined
AI要約
Background and causes of postponement
Takara Holdings Co., Ltd. announced that the disclosure of the Q1 2027 earnings summary is expected to exceed 45 days after the quarter end. The direct cause of the postponement is that questions about the accounting treatment of our consolidated subsidiary Takara Bio USA, Inc. were pointed out by the auditors, and further investigation is required to establish factual relationships. We are conducting the investigation with the legal team and accountants, and the timing of the earnings announcement after the postponement is currently undetermined.
Upcoming schedule and impact
Currently, the investigation of facts is continuing with legal professionals and certified public accountants. Once a new decision date is determined, we will promptly disclose it. To avoid confusion for the board of directors and investors, timely information will continue to be provided to relevant parties. Takara Bio USA, Inc.’s overview and the past three years’ sales trends are disclosed as reference information.
Takara Holdings Co., Ltd.
Company overview · Stock price · Financial data · All IR
